Last updated on January 2019
A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered Locally Advanced or Metastatic Triple-Negative Breast Cancer or Hormone Receptor-Positive HER2-Negative Breast Cancer
Brief description of study
This study will evaluate the efficacy of ipatasertib + paclitaxel versus placebo + paclitaxel in participants with histologically confirmed, locally advanced or metastatic triple-negative breast cancer (TNBC) and in participants with locally advanced or metastatic hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2) breast adenocarcinoma who are not suitable for endocrine therapy.
Clinical Study Identifier: NCT03337724
Start Over
Reference Study ID: CO40016 www.roche.com/about_roche/roche_worldwide.htm
Santa Casa de Misericordia de Salvador; Oncologia Salvador, Brazil0.08miles
Connect »